A phase 2 study of single agent ibrutinib for first‐line treatment of chronic graft‐versus‐host disease: A new paradigm and lessons learned
The authors declare no conflicts of interest. There is no data available or eligible to be made accessible. Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Authors
- William D. Figg (ORCID: https://orcid.org/0000-0002-5875-2606)
- Anita Stokes
- Najla El Jurdi (ORCID: https://orcid.org/0000-0002-9268-9655)
- Edward W. Cowen (ORCID: https://orcid.org/0000-0003-1918-4324)
- Eduard Schulz (ORCID: https://orcid.org/0000-0002-6672-4592)
- Keith Thomas Schmidt (ORCID: https://orcid.org/0009-0008-0285-0216)
- N Micheletti
- Iskra Pusic (ORCID: https://orcid.org/0000-0003-1725-5184)
- Alain Mina (ORCID: https://orcid.org/0000-0002-4388-4825)
- Steven Zivko Pavletic (ORCID: https://orcid.org/0000-0001-9111-9354)
- Jacqueline Wiesehan Mays (ORCID: https://orcid.org/0000-0002-4472-9974)
- Noa G. Holtzman (ORCID: https://orcid.org/0000-0002-5706-1109)
- Grace Li (ORCID: https://orcid.org/0000-0002-6661-0421)
- Rania Hishmeh
Institutions
- National Institutes of Health (US)
- University of Miami (US)
- Washington University in St. Louis (US)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (US)
- National Institute of Dental and Craniofacial Research (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- Sylvester Comprehensive Cancer Center (US)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1111/bjh.20069
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.63